Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations
Petros P. Sfikakis(National and Kapodistrian University of Athens), Hasan Yazıcı(Istanbul University), Samir H. Assaad‐Khalil(King's College London), Nicolò Pipitone(King's College London), Michael Schirmer(King's College London), Miles Stanford(Imperial College Healthcare NHS Trust), Shigeo Ohno(Juntendo University), Erkan Alpsoy(Akdeniz University Hospital), P Kaklamanis, Bahram Bodaghi(Sorbonne Université), B. Wechsler(King's College London), Ahmet Gül(Istanbul University), Nikos N. Markomichelakis, Christos C. Zouboulis(Freie Universität Berlin)
Cited by 301
Related Papers
2018 update of the EULAR recommendations for the management of Behçet's syndrome
|Annals of the Rheumatic Diseases|2018|771
The Long-Term Mortality and Morbidity of Behçet Syndrome
|Medicine|2003|757
EULAR recommendations for the management of Behçet disease
|Annals of the Rheumatic Diseases|2008|721
A Controlled Trial of Azathioprine in Behçet's Syndrome
|New England Journal of Medicine|1990|646
Behçet syndrome: a contemporary view
|Nature Reviews Rheumatology|2018|438